<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>381</serviceExecutionTime><Drug id="55488"><DrugName>lanabecestat</DrugName><DrugNamesKey><Name id="43076243">lanabecestat</Name><Name id="43086054">lanabecestat camsylate</Name></DrugNamesKey><DrugSynonyms><Name><Value>BACE inhibitors (Alzheimer's disease), AstraZeneca/Astex</Value></Name><Name><Value>beta secretase inhibitors (Alzheimer's disease), AstraZeneca/Astex</Value></Name><Name><Value>AZ-12304146</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AZ-20, Astex</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AZ-36</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AZ-71</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AZ-13</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AZ-78</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BACE inhibitors (Alzheimer's disease), AstraZeneca/SuperGen</Value></Name><Name><Value>AZ-17, Astrazeneca</Value></Name><Name><Value>BACE inhibitor (Alzheimer's disease), AstraZeneca/Eli Lilly</Value></Name><Name><Value>lanabecestat</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>AZD-3293</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LY-3314814</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>lanabecestat camsylate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>LY-3314814 camsylate</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AZD-3293 camsylate</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1383982-64-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1522418-41-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="28026">Astex Therapeutics Ltd</CompanyOriginator><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company><Company id="17810">Eli Lilly &amp; Co</Company><Company id="21885">Astex Pharmaceuticals Inc</Company><Company id="28026">Astex Therapeutics Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55488" type="Drug"><TargetEntity id="781934" type="siDrug"></TargetEntity><TargetEntity id="764573" type="siDrug"></TargetEntity><TargetEntity id="764569" type="siDrug"></TargetEntity><TargetEntity id="764577" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="21885" type="Company"><TargetEntity id="4295908050" type="organizationId">Astex Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="28026" type="Company"><TargetEntity id="4297146302" type="organizationId">Astex Therapeutics Ltd</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="9308" type="Action"><TargetEntity id="2289" type="Mechanism">beta-Secretase 2 (BACE2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="9305" type="Action"><TargetEntity id="2288" type="Mechanism">beta-Secretase 1 (BACE1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7343" type="Action"><TargetEntity id="2200" type="Mechanism">Anti-A beta Peptide</TargetEntity><TargetEntity id="966" type="Mechanism">beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-02142" type="ciTarget"><TargetEntity id="1244415668236213" type="siTarget">Beta-secretase 1</TargetEntity><TargetEntity id="-1712717656" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-02143" type="ciTarget"><TargetEntity id="968534151258253" type="siTarget">Beta-secretase 2</TargetEntity><TargetEntity id="-1019552752" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="7343">Beta amyloid antagonist</Action><Action id="9305">Beta secretase 1 inhibitor</Action><Action id="9308">Beta secretase 2 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-06T08:21:35.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>2006-06-01T12:39:42.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; in collaboration with &lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly &amp;amp; Co&lt;/ulink&gt;,  and initially in collaboration with   &lt;ulink linkID="21885" linkType="Company"&gt;Astex Pharmaceuticals&lt;/ulink&gt; (previously known as SuperGen and a wholly owned subsidiary of &lt;ulink linkID="18717" linkType="Company"&gt;Otsuka Pharmaceutical&lt;/ulink&gt; following its acquisition of Astex),  was developing lanabecestat (AZD-3293, LY-3314814), the lead from a program of beta amyloid secretase  (BACE) inhibitors,  also including the BACE1 inhibitors AZ-13 and  AZ-17, as an oral tablet  for the potential treatment of Alzheimer's disease (AD) [&lt;ulink linkID="480664" linkType="Reference"&gt;480664&lt;/ulink&gt;],  [&lt;ulink linkID="1594095" linkType="Reference"&gt;1594095&lt;/ulink&gt;], [&lt;ulink linkID="1616790" linkType="Reference"&gt;1616790&lt;/ulink&gt;], [&lt;ulink linkID="2012067" linkType="Reference"&gt;2012067&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, the phase III DAYBREAK study for mild Alzheimer's dementia began [&lt;ulink linkID="1777734" linkType="Reference"&gt;1777734&lt;/ulink&gt;], [&lt;ulink linkID="1902319" linkType="Reference"&gt;1902319&lt;/ulink&gt;]. In April 2016, the phase III portion of the   phase II/III AMARANTH study commenced in  prodromal and mild AD [&lt;ulink linkID="1756099" linkType="Reference"&gt;1756099&lt;/ulink&gt;], [&lt;ulink linkID="1902319" linkType="Reference"&gt;1902319&lt;/ulink&gt;]; at that time, the drug was listed as being in phase III development in Japan on Eli Lilly Japan's pipeline for progress inhibition of early Alzheimer's dementia [&lt;ulink linkID="1983525" linkType="Reference"&gt;1983525&lt;/ulink&gt;]; this was still the case in October 2017 [&lt;ulink linkID="1983392" linkType="Reference"&gt;1983392&lt;/ulink&gt;]. However, in June 2018, AstraZeneca discontinued the phase III AMARANTH trial (including the extension trial) and DAYBREAK-ALZ trial based on the conclusion of the  independent data monitoring committee (IDMC) that the studies were not likely to meet their primary endpoints [&lt;ulink linkID="2043458" linkType="Reference"&gt;2043458&lt;/ulink&gt;]. In April 2019, AstraZeneca had planned to terminate the collaboration with Lilly [&lt;ulink linkID="2145515" linkType="Reference"&gt;2145515&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AstraZeneca was also previously developing &lt;ulink linkID="71541" linkType="Drug"&gt;AZD-3839&lt;/ulink&gt;,  a BACE inhibitor  for AD presumed to be from    this program.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2016, the drug received Fast Track designation  from the FDA for AD  [&lt;ulink linkID="1789977" linkType="Reference"&gt;1789977&lt;/ulink&gt;]; in March 2018, a US filing for AD based on AMARANTH + extension and DAYBREAK-ALZ trials was expected in 2020 [&lt;ulink linkID="2011763" linkType="Reference"&gt;2011763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2018, an EU filing for AD based on AMARANTH + extension and DAYBREAK-ALZ trials was expected in 2020 [&lt;ulink linkID="2011763" linkType="Reference"&gt;2011763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;in March 2018, a Japanese filing for AD based on AMARANTH + extension and DAYBREAK-ALZ trials was expected in 2020 [&lt;ulink linkID="2011763" linkType="Reference"&gt;2011763&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2017, a randomized, double-blind, parallel-assigned, phase III trial (&lt;ulink linkID="280248" linkType="Protocol"&gt;NCT02972658&lt;/ulink&gt;; 16557; I8D-MC-AZFD; 2016-003440-36) as an extension to AMARANTH  study, was  initiated in the US, Australia, Canada, Germany, South Korea, Poland, Spain and the UK to evaluate the efficacy of lanabecestat in patients (expected n = 1400) with early Alzheimer's disease dementia. At that time, the study was to complete in July 2020 [&lt;ulink linkID="1906502" linkType="Reference"&gt;1906502&lt;/ulink&gt;]; in March 2018, the trial was ongoing [&lt;ulink linkID="2011763" linkType="Reference"&gt;2011763&lt;/ulink&gt;]. In June 2018, AstraZeneca discontinued the  trial AMARANTH extension trial based on the recommendation of the  IDMC  [&lt;ulink linkID="2043458" linkType="Reference"&gt;2043458&lt;/ulink&gt;]. In December 2018, the results of the trial supported that discontinuation of the trial was justified as no significant efficacy signal was observed [&lt;ulink linkID="2119607" linkType="Reference"&gt;2119607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, a phase III trial (DAYBREAK) was planned to be initiated in 3Q16 to study the safety and efficacy of lanabecestat in people with mild Alzheimer's dementia [&lt;ulink linkID="1749867" linkType="Reference"&gt;1749867&lt;/ulink&gt;], [&lt;ulink linkID="1749898" linkType="Reference"&gt;1749898&lt;/ulink&gt;]. In August 2016, the double-blind, placebo-controlled, randomized, delayed start, phase III study (&lt;ulink linkID="261850" linkType="Protocol"&gt;NCT02783573&lt;/ulink&gt;; DAYBREAK-ALZ;16024  I8D-MC-AZET  2015-005625-39) began in  patients (expected n = 1899) with mild Alzheimer's dementia in the US, Canada, Europe, Japan, South Korea, Taiwan and Mexico. The primary endpoint was was change from baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13). In January 2018,  the study was to complete in March 2021.  [&lt;ulink linkID="1777734" linkType="Reference"&gt;1777734&lt;/ulink&gt;], [&lt;ulink linkID="1902319" linkType="Reference"&gt;1902319&lt;/ulink&gt;]. In June 2018, AstraZeneca discontinued the  trial based on the conclusion of the  IDMC that the trial was not likely  to meet its primary endpoint  [&lt;ulink linkID="2043458" linkType="Reference"&gt;2043458&lt;/ulink&gt;]. In December 2018, the results of the trial supported that discontinuation of the trial was justified as no significant efficacy signal was observed [&lt;ulink linkID="2119607" linkType="Reference"&gt;2119607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, a  phase II/III, 24-month, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety, tolerability, biomarker and pharmacokinetic trial (&lt;ulink linkID="211201" linkType="Protocol"&gt;NCT02245737&lt;/ulink&gt;; D5010C00009; 16023; I8D-MC-AZES; 2014-002601-38; AMARANTH) was initiated in the US, Argentina, Europe, Canada, Australia, Japan and  South Korea in patients (n = 1551) with early (prodromal and mild) AD. The primary endpoint was the change from baseline in the clinical dementia rating - sum of boxes (CDR-SB) score  [&lt;ulink linkID="1605545" linkType="Reference"&gt;1605545&lt;/ulink&gt;]. In December 2014, the first patient was enrolled   [&lt;ulink linkID="1616790" linkType="Reference"&gt;1616790&lt;/ulink&gt;]. In August 2015, the trial was expected to recruit 2202 patients and to complete in August 2021 [&lt;ulink linkID="1605545" linkType="Reference"&gt;1605545&lt;/ulink&gt;]. In April 2016, it was reported that the trial would continue from phase II to phase III following a positive interim safety analysis [&lt;ulink linkID="1749867" linkType="Reference"&gt;1749867&lt;/ulink&gt;], [&lt;ulink linkID="1749898" linkType="Reference"&gt;1749898&lt;/ulink&gt;]; later that month, Lilly was listing the drug as having moved from phase II into phase III [&lt;ulink linkID="1756099" linkType="Reference"&gt;1756099&lt;/ulink&gt;], [&lt;ulink linkID="1902319" linkType="Reference"&gt;1902319&lt;/ulink&gt;]. In July 2017, a  second interim analysis of the phase III study was completed. At that time, and the independent data monitoring committee recommended the trial proceed with no modifications   [&lt;ulink linkID="1948273" linkType="Reference"&gt;1948273&lt;/ulink&gt;], [&lt;ulink linkID="2011763" linkType="Reference"&gt;2011763&lt;/ulink&gt;]. In January 2018,  the study was to complete in September 2019 [&lt;ulink linkID="1605545" linkType="Reference"&gt;1605545&lt;/ulink&gt;]. In June 2018, AstraZeneca discontinued the  trial based on the conclusion of the  IDMC that the trial was not likely  to meet its primary endpoint  [&lt;ulink linkID="2043458" linkType="Reference"&gt;2043458&lt;/ulink&gt;]. In December 2018, the results of the trial supported that discontinuation of the trial was justified as no significant efficacy signal was observed [&lt;ulink linkID="2119607" linkType="Reference"&gt;2119607&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In March 2018, clinical data from an open-label, fixed-sequence, two-period study (&lt;ulink linkID="239592" linkType="Protocol"&gt;NCT02540668&lt;/ulink&gt;) evaluating the safety, pharmacokinetics and pharmacodynamics of lanabecestat and warfarin in healthy male subjects were presented at the 119th ASCPT Annual Meeting in Orlando, FL. Subjects (n = 15) received warfarin (15 mg) alone or after 14 daily doses of lanabecestat (50 mg). In period 1, subjects received single-dose of 15 mg warfarin, po on day 1 and day 7 washout; in period 2, subjects received lanabecestat qd on days 8 to 27, with a single-dose of 15 mg warfarin, po, co-administered on day 22. In overall group, abdominal pain, epistaxis and retinal haemorrhage (mild in severity) were the most commonly reported treatment-emergent adverse events. In warfarin versus warfarin + lanabecestat groups, for S-warfarin, the mean unbound AUC 0 to infinity and Cmax values were 108 versus 124 ngxh/ml and 3.50 versus 3.73 ng/ml, respectively; fraction bound AUC 0 to infinity and Cmax values were 0.9957 versus 0.9954 ng x h/ml and 0.9960 versus 0.9961 ng/ml, respectively; and median Tmax value was 1 versus 1 h (p = 0.9424), respectively [&lt;ulink linkID="2015948" linkType="Reference"&gt;2015948&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, a clinical trial was filed in China [&lt;ulink linkID="1785293" linkType="Reference"&gt;1785293&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;n March 2015, clinical data were presented from a phase I, randomized, double-blind, placebo-controlled, two-part, multiple ascending dose study (&lt;ulink linkID="111535" linkType="Protocol"&gt;NCT01795339&lt;/ulink&gt;) in healthy young and elderly adults (part one) and in 16 patients with Alzheimer's disease (AD; part two) at the AD/PD 2015 International Conference in Nice, France. In part two, patients (n = 16) were randomized (3:1; n = 4/cohort) to receive lanabecestat (15, 50 or 150 mg) or placebo as a single dose on day 1 followed by multiple daily doses on days 3 through 14. Overall, lanabecestat was safe and well tolerated. On day 14, there was a significant decrease in CSF amyloid-beta 1 to 40 and amyloid-beta 1 to 42 concentrations observed with all lanabecestat doses tested when compared with baseline [&lt;ulink linkID="1640973" linkType="Reference"&gt;1640973&lt;/ulink&gt;]. In November 2014, further clinical data were presented at CTAD 2014 in Philadelphia, PA. CSF Abeta (1-42) levels were decreased by 52, 76 and 90% when compared with baseline for 15, 50 and 150 mg of lanabecestat dose groups, respectively, while the reduction was 6% for placebo [&lt;ulink linkID="1686158" linkType="Reference"&gt;1686158&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  February 2014, an open-label, interventional, randomized, single-dose, three-period, cross-over, phase I study (&lt;ulink linkID="167963" linkType="Protocol"&gt;NCT02039180&lt;/ulink&gt;; D5010C00005) was initiated to compare two solid formulations with solution form of oral lanabecestat in healthy male and non-fertile female subjects (expected n = 16) in the US. At that time, the trial was expected to be completed in March 2014 [&lt;ulink linkID="1519664" linkType="Reference"&gt;1519664&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, a randomized, placebo-controlled, double-blind, parallel assignment, single and multiple ascending dose, phase I study (&lt;ulink linkID="163168" linkType="Protocol"&gt;NCT02005211&lt;/ulink&gt;, D5010C00003) was initiated in healthy Japanese volunteers (expected n = 40) [&lt;ulink linkID="1569442" linkType="Reference"&gt;1569442&lt;/ulink&gt;].    In July 2016, data were presented at the 2016 AAIC in Toronto, Canada. After multiple dosing, lanabecestat plasma t1/2 was 14 to 16 h.  Cmax and AUC in part 1 was 82.5, 396 and 1480 ng/ml; and 864, 2850 and 10700 h.ng/ml in 15, 50 and 150 mg lanabecestat groups (n = each 6), respectively. Cmax and AUCtau at steady state in part 2 was 119 and 502 ng/ml; and 1030 and 3280 h.ng/ml in 15 and 50 mg lanabecestat groups (n = 5 and 6), respectively. At all doses tested, significant and sustained suppression of plasma Abeta1-42 reduction was observed [&lt;ulink linkID="1782055" linkType="Reference"&gt;1782055&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, data from phase I trials were presented at the 6th Clinical Trials Conference on Alzheimer's Disease in San Diego, CA. The data demonstrated  that lanabecestat lowered beta amyloid in cerebrospinal fluid up to 75% and had taken two to three weeks to return to baseline after treatment [&lt;ulink linkID="1531612" linkType="Reference"&gt;1531612&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, a randomized, double-blind, placebo-controlled, phase I trial (&lt;ulink linkID="100413" linkType="Protocol"&gt;NCT01739647&lt;/ulink&gt;, D5010C00001) was initiated in healthy young and  elderly volunteers (expected n = 96) in the US.  At that time, the trial was expected to complete in May 2013 [&lt;ulink linkID="1365021" linkType="Reference"&gt;1365021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Otherstudies&lt;/subtitle&gt;In March 2018, data from an open-label, fixed-sequence, 2-period study (&lt;ulink linkID="242222" linkType="Protocol"&gt;NCT02568397&lt;/ulink&gt;) performed to evaluate the pharmacokinetic and pharmacodynamic of lanabecestat and dabigatran etexilate, been developed for the potential treatment of alzheimer’s disease, in healthy subjects was presented at 119th ASCPT Annual Meeting in Orlando, FL. Subjects (n = 60, enrolled) received single doses of dabigatran etexilate 150 mg alone or with lanabecestat 50 mg qd followed by lanabecestat and dabigatran etexilate on day 16 (period 2), dabigatran etexilate was dosed 4 h after lanabecestat on day 20. No dabigatran etexilate induced effect on lanabecestat AUCT.SS (3360, 3300 and 3490 ng.h/ml, respectively) or C max (342, 315 and 331 ng/ml, respectively) values were observed. No effect of lanabecestat administration with dabigatran etexilate on dabigatran-induced change in thrombin time was observed [&lt;ulink linkID="2015934" linkType="Reference"&gt;2015934&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By November 2017, a series of dispiro compounds had been synthesized as BACE1 inhibitors. One of the most potent compounds, displayed a high binding affinity with a Ki value of 16 nM for BACE1 [&lt;ulink linkID="2042132" linkType="Reference"&gt;2042132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, in vivo data from toxicology studies conducted in albino rats and Beagle dogs were presented at the 56th Society of Toxicology Annual Meeting in Baltimore, MD. In beagle dogs, 4-week treatment with AZD-3293 (qd, po) was associated with dose-dependent skin and fur discolorations around the eye, whiskers (vibrissae), muzzle and back saddle. Dose-related pigmentation changes included decreased pigmentation in the skin, mucosa and hair bulbs in Long Evans rat and Beagle dogs. A striped coloration pattern on the whiskers was developed by dogs treated with AZD-3293 (qw, po), which correlated with marked reductions in melanin in the epidermal and hair follicle keratinocytes as well as with alterations in the morphological appearance of melanocytes [&lt;ulink linkID="1921199" linkType="Reference"&gt;1921199&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2012, a series of compounds based on four different cores structures, five and six-membered bicyclic and monocyclic cores, had been synthesized. One of the most potent compounds from the five-membered monocyclic core exhibited IC50 values of 0.79 and  0.40 microM in the biochemical and cell based assays, respectively. The compound displayed good brain exposure in mice (iv, 30-50 micromol/kg) with a  total brain/plasma ratio of 1.3 [&lt;ulink linkID="1428022" linkType="Reference"&gt;1428022&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2012, a series of amino-2H-imidazoles had been synthesized as BACE-1 inhibitors. One of the best compounds exhibited an IC50 value of 24 nM for BACE-1, was selective over hERG (IC50 &amp;gt; 33 microM) and reduced brain amyloid-beta peptide by 40-50% in male guinea pigs (100 micromol/kg, po) [&lt;ulink linkID="1339514" linkType="Reference"&gt;1339514&lt;/ulink&gt;], [&lt;ulink linkID="1339269" linkType="Reference"&gt;1339269&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, preclinical data were presented at the Alzheimer's Association International Conference 2012 in Vancouver, Canada. Between the primary cortical neurons from C57BL/6 or Tg2576 mice, po AZ-17 demonstrated a difference in potency in vitro. In C57BL/6 mice, AZ-17 demonstrated reduction in brain beta-amyloid (Abeta) in a dose- and time-dependent manner. In Tg2576 mice, after 28 days of AZ-17 treatment, the insoluble pool of Abeta was reduced [&lt;ulink linkID="1307978" linkType="Reference"&gt;1307978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, preclinical data were presented at the 41st SFN Meeting in Washington DC. In primary mouse cortical neurons and the N2A mouse cell line, AZ-13 displayed concentration-dependent inhibition of amyloid beta (Abeta) release with IC50 values of 34 and 23 nM, respectively. Future research would involve confirmation of in vivo brain penetration of compounds of interest [&lt;ulink linkID="1235892" linkType="Reference"&gt;1235892&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, preclinical data were presented at AD/PD 2011 in Barcelona, Spain. In  one study, C57BL/6 mice administered with a single po dose of   AZ-13 (50, 75, 100 or 300 micromol/kg), demonstrated a concentration-dependent decrease in Abeta40, Abeta42 and sAPPbeta levels in brain and plasma [&lt;ulink linkID="1175568" linkType="Reference"&gt;1175568&lt;/ulink&gt;]. In a further study, a concentration-dependent decrease of Abeta  levels was observed in the brain and plasma of male Dunklin Hartley guinea pigs (n = 6) administered with compound AZ-78 (po, 50, 100 or 200 micromol/kg) [&lt;ulink linkID="1175608" linkType="Reference"&gt;1175608&lt;/ulink&gt;].  In July 2013, further data were presented at the Alzheimer's Association International Conference 2013 in Boston, MA. Lanabecestat showed Ki value of 0.4 nM for human BACE-1. The t1/2 of lanabecestat was 8 h. In female C57B16 mice, brain AB was reduced to a maximum level by 6 h and returned to baseline by 16 h. The EC50 value of brain AB40 reduction was 0.6 nmol/l in mice. In male Dunkin-Hartley guinea pigs, brain AB was reduced to a maximum level by 4 h but did not return to baseline by 24 h. The EC50 value of brain AB40 reduction was 1.1 nmol/l [&lt;ulink linkID="1452343" linkType="Reference"&gt;1452343&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, preclinical data on AZ-20, AZ-36 and AZ-71 were presented at the 12th ICAD meeting in Vienna, Austria. In vivo, these BACE inhibitors were shown to inhibit Abeta in brain and plasma in various animal  models [&lt;ulink linkID="1022142" linkType="Reference"&gt;1022142&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, preclinical data on BACE inhibitors were presented at the 233rd ACS National Meeting in Chicago, IL. In the study, fragment based lead generation methods were used to identify compound structures with weak affinity for the BACE active site. This structure based  research led to the generation of  a series of isocytosine-based inhibitors.  One compound was identified with an IC50 value of 6 microM [&lt;ulink linkID="773536" linkType="Reference"&gt;773536&lt;/ulink&gt;]. In a further study, a combination of database mining, crystallography, NMR spectroscopy and molecular modeling methodology resulted in a novel series of dihydroisocytosine-based inhibitors with  IC50 values of &amp;lt; 100 nM.  The single enantiomer of one compound, with an IC50 value of 0.08 microM was finally identified [&lt;ulink linkID="773537" linkType="Reference"&gt;773537&lt;/ulink&gt;]. In August 2007, similar data were presented at the 234th ACS meeting in Boston, MA [&lt;ulink linkID="817871" linkType="Reference"&gt;817871&lt;/ulink&gt;]. In September 2008, similar data were presented at the XXth EFMC-ISMC in Vienna, Austria [&lt;ulink linkID="935165" linkType="Reference"&gt;935165&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2006, preclinical data were presented at the Fifth SCI-RSC Proteinase Inhibitor Design Symposium in London, UK. AZ-12304146 showed sub-micromolar potency (670 nM) and activity in a cell based APP assay. Extension of the hydrophobic residue with an ethylene spacer enhanced potency 3-fold while resolution of the two enantiomers gave a compound with 80 nM potency, with the methoxybiphenyl residue providing a good fit into the S1-S3 subsite [&lt;ulink linkID="670659" linkType="Reference"&gt;670659&lt;/ulink&gt;]. In March 2007, these data were presented at Fragments 2007 in Cambridge, UK [&lt;ulink linkID="775402" linkType="Reference"&gt;775402&lt;/ulink&gt;]. In November 2007, data on the same compound were published [&lt;ulink linkID="864774" linkType="Reference"&gt;864774&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21885">Astex Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-31T00:00:00.000Z</StatusDate><Source id="1365021" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-12T00:00:00.000Z</StatusDate><Source id="2043458" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-04T00:00:00.000Z</StatusDate><Source id="480664" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21885">Astex Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-21T00:00:00.000Z</StatusDate><Source id="1209053" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-31T00:00:00.000Z</StatusDate><Source id="1365021" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-16T00:00:00.000Z</StatusDate><Source id="1594095" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="1569442" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-16T00:00:00.000Z</StatusDate><Source id="1594095" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-05T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-05T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1777734" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1777734" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1777734" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1777734" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-04-26T00:00:00.000Z</StatusDate><Source id="1983525" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1605545" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-05T00:00:00.000Z</StatusDate><Source id="1785293" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-05T00:00:00.000Z</StatusDate><Source id="1785293" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28026">Astex Therapeutics Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-04T00:00:00.000Z</StatusDate><Source id="480664" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="US">US</Country><Indication id="14">Alzheimers disease</Indication><AwardedIndication>Treatment of Alzheimer's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-22T00:00:00.000Z</MileStoneDate><Source id="1789977" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00134"><Name>Beta amyloid</Name><SwissprotNumbers><Swissprot>O73683</Swissprot><Swissprot>O93279</Swissprot><Swissprot>P05067</Swissprot><Swissprot>P08592</Swissprot><Swissprot>P12023</Swissprot><Swissprot>P14599</Swissprot><Swissprot>P29216</Swissprot><Swissprot>P53601</Swissprot><Swissprot>P79307</Swissprot><Swissprot>Q10651</Swissprot><Swissprot>Q28053</Swissprot><Swissprot>Q28280</Swissprot><Swissprot>Q28748</Swissprot><Swissprot>Q28757</Swissprot><Swissprot>Q29149</Swissprot><Swissprot>Q5IS80</Swissprot><Swissprot>Q60495</Swissprot><Swissprot>Q95241</Swissprot></SwissprotNumbers></Target><Target id="PTGT-02142"><Name>Beta secretase 1</Name><SwissprotNumbers><Swissprot>P56817</Swissprot><Swissprot>P56818</Swissprot><Swissprot>P56819</Swissprot></SwissprotNumbers></Target><Target id="PTGT-02143"><Name>Beta secretase 2</Name><SwissprotNumbers><Swissprot>Q9Y5Z0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2145515" linkType="reference" linkID="2145515"&gt;2145515&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1040632">Otsuka Holdings Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC1(CC(=O)N(C(=N1)N)C)c2cccc(c2)c3cccc(c3)OC</Smiles><Smiles>Cc1cc(cc(c1OC)C)[C@]2(N=C(C(=N2)N)C)c3cccc(c3)c4cncnc4</Smiles><Smiles>CC1(CC(=O)N(C(=N1)N)C)CCc2cccc(c2)c3cccc(c3)OC</Smiles><Smiles>Cc1cc(cc(c1OC)C)[C@]2(c3c(nccn3)C(=N2)N)c4cccc(c4)c5cncnc5</Smiles><Smiles>COc1ccc(cc1)C2(N=C(CS2)N)c3cccc(c3)c4cccnc4</Smiles><Smiles>CC#Cc1cncc(c1)c2cc3c(cc2)C[C@@]4([C@@]35N=C(C(=N5)C)N)CC[C@H](CC4)OC.CC1([C@@]2(C(=O)C[C@H]1CC2)CS(=O)(=O)O)C</Smiles><Smiles>CC#Cc1cncc(c1)c2cc3c(cc2)C[C@@]4([C@@]35N=C(C(=N5)C)N)CC[C@H](CC4)OC</Smiles><Smiles>[2H]C1([C@@]2(c3cc(ccc3C[C@@]24CC[C@@H]([C@H](C4)C)OC)c5cncnc5)N=C(O1)N)[2H]</Smiles></StructureSmiles><Deals><Deal id="111887" title="Astex and AstraZeneca to discover and develop Alzheimer's disease therapeutics       "></Deal><Deal id="150846" title="AstraZeneca and Eli Lilly to codevelop and commercialize AZD-3293 against Alzheimers disease "></Deal></Deals><PatentFamilies><PatentFamily id="2658708" number="WO-2013190302" title="Camsylate salt"></PatentFamily><PatentFamily id="2802393" number="US-20140271911" title="Lithium and a beta-secretase inhibitor for the treatment of Alzheimer's disease"></PatentFamily><PatentFamily id="3180151" number="WO-2016055858" title="Compounds and their use as BACE inhibitors"></PatentFamily><PatentFamily id="3254513" number="US-20160213645" title="Combination of levetiracetam and a beta-secretase (BACE) inhibitor"></PatentFamily><PatentFamily id="3795295" number="WO-2017158064" title="Combination of a BACE  inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid β"></PatentFamily><PatentFamily id="3795749" number="WO-2017160622" title="Combination therapy"></PatentFamily><PatentFamily id="4561908" number="WO-2019122268" title="Processes for the stereoselective preparation of bace inhibitors"></PatentFamily><PatentFamily id="4561975" number="WO-2019122421" title="Stereoselective ketone reduction using a ketoreductase enzyme"></PatentFamily><PatentFamily id="600388" number="WO-2012087237" title="Compounds and their use as BACE inhibitors"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York University" id="20646"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Rochester" id="20669"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>